Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26125969 | 1.00 | HDAC6 (0.51) | HDAC6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL26530718 | 0.92 | HDAC6 (0.45) | HDAC6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL31660716 | 0.90 | HDAC6 (0.47) | HDAC6MAPTPOLBSMN1; SMN2MEN1 | |
| SCHEMBL26529884 | 0.88 | HDAC6 (0.49) | HDAC6HDAC1 | |
| SCHEMBL34463622 | 0.88 | HDAC6 (0.51) | HDAC6HDAC1 | |
| SCHEMBL26529877 | 0.88 | HDAC6 (0.51) | HDAC6HDAC1 | |
| SCHEMBL30574338 | 0.85 | HDAC6 (0.55) | HDAC6HDAC1 | |
| SCHEMBL26127581 | 0.85 | HDAC6 (0.55) | HDAC6HDAC1 | |
| SCHEMBL26529911 | 0.84 | HDAC6 (0.50) | HDAC6HDAC1 | |
| SCHEMBL26529791 | 0.84 | HDAC6 (0.49) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4504191-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4504191-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4504190-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119212707-A | Oxadiazole HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | HDAC6, HDAC1, HDAC9 | HDAC6 1/4885KDM4E 1593/4885ALDH1A1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.